International differences in drug prices

Annual Review of Public Health

Volumn 25, Issue , 2004, Pages 475-495

  Wagner, Judith L ^a   McCarthy, Elizabeth ^a  

^a INSTITUTE OF MEDICINE   (United States)

Author keywords

Drug price regulation; Pharmaceutical research and development; Prescription drugs; Price discrimination

Indexed keywords

DATA ANALYSIS; DECISION MAKING; DRUG COST; ECONOMIC ASPECT; HUMAN; INCOME; INSURANCE; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; UNITED STATES;

DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HUMANS; INTERNATIONAL COOPERATION; UNITED STATES;

EID: 2142825070     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.25.101802.123042     Document Type: Review

References (50)

1. Angus DE, Karpetz HM. 1998. Pharmaceutical policies in Canada: issues and challenges. Pharmacoeconomics 14(Suppl. 1):81-96
2. Aronovitz LG. 1994. Letter: Prescription drug prices in France. Aug. 12. U.S. Gen. Account. Off. GAO/HEHS-94-200R. Washington, DC
3. Berndt ER. 2000. International comparisons of pharmaceutical prices: what do we know, and what does it mean? J. Health Econ. 19(2):283-87
4. Calfee JE. 2000. Prices, Markets, and the Pharmaceutical Revolution. Washington, DC: AEI
5. Cent. Medicare Medicaid Serv. 2003. Medicare Current Beneficiary Survey. Baltimore, MD. http://cms.hhs.gov/mcbs
6. Corvari RJ. 1998. Trends in patented drug prices. Pat. Med. Prices Rev. Board, Canada. Study Ser., S09811
7. Danzon PM. 1996. The uses and abuses of international price comparisons. In Competitive Strategies in the Pharmaceutical Industry, ed. RB Helms, pp. 85-106. Washington, DC: AEI
8. Danzon PM. 1997. Pharmaceutical Price Regulation: National Policies Versus Global Interests. Washington, DC: AEI
9. Danzon PM, Chao LW. 2000. Cross-national price differences for pharmaceuticals: how large, and why? J. Health Econ. 19(2):159-95
10. Danzon PM, Kim JD. 1998. International price comparisons for pharmaceuticals. Measurement and policy issues. Pharmacoeconomics 14(Suppl. 1): 115-28
11. Deleted in proof
12. Deleted in proof
13. Dingwall D. 1997. Drug costs in Canada. Submitted to the House of Commons Stand. Comm. Ind. Ottawa, Canada
14. Frank RG. 2001. Prescription drug prices: Why do some pay more than others do? Health Aff. 20(2):115-28
15. Greider K. 2003. The Big Fix: How the Pharmaceutical Industry Rips Off American Consumers. New York: Public Affairs
16. Gross DJ, Ratner J, Perez J, Glavin SL. 1994. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom. Health Care Financ.Rev. 15(3): 127-40
17. Gruber J. 2000. Health insurance and the labor market. In Handbook of Health Economics.Vol. 1A: Health Insurance and the Labor Market, ed. AJ Culyer, JP Newhouse, pp. 646-706. New York: Elsevier
18. Hirschler B. 2003. Pharmaceutical companies said on Tuesday that they were increasing the supply of life-saving AIDS medicines to Africa. Accessed 14 Jan. Reuters Health http://www.reuters health.com
19. Hurley J, Johnson NA. 1991. The effects of co-payments within drug reimbursement programs. Can. Public Pol.-Analyse de Politiques. XVII(4):473-89
20. Jaggar SF. 1994. Prescription drugs: prices and regulation in Canada and Europe. Testimony before Comm. Gov. Aff., US Senate. US Gen. Account. Off. GAO/T-HEHS-94-213. Washington, DC
21. Kaiser Family Found. Health Res. Educ. Trust. 2003. Employer Health Benefits, 2003 Annual Survey. Menlo Park, CA: Kaiser Family Found, http://www.kff.org/ content/2003/20030909a/Chartpackv2.pdf
22. Kanavos P. 2001. Overview of pharmaceutical pricing and reimbursement regulation in Europe. Work. Pap. London Sch. Econ. Health Soc. Care
23. Koppel N. 2003. Health bodies launch research push to find cures for unfashionable diseases. Geneva, Switz., Assoc. Press Worldwide. July 3
24. Kremer M. 2002. Pharmaceuticals and the developing world. J. Econ. Perspect. 16(4):67-90
25. Maynard A, Bloor K. 2003. Dilemmas in regulation of the market for pharmaceuti-cals. Health Aff. 20(3):31-41
26. Med. Econ. 1995. Drug Topics Redbook. Montvale, NJ: Med. Econ.
27. Morgan SG, Barer ML, Agnew JD. 2003. Whither seniors' pharmacare: lessons from (and for) Canada. Health Aff. 22(3):49-59
28. Natl. Assoc. Chain Drug Stores. 2003. Industry statistics. Accessed 21 July http:// www.nacds.org/wmspage. cfm?parm 1= 507
29. Olson M. 1995. The effects of UK pharmaceutical policy on government drug expenditure: cost control and incentives for R&D. Int. J. Econ. Bus. 2(1):51-64
30. Pat. Med. Prices Rev. Board. 2000. Trends in Drug Prices and Expenditures. Annu. Rep. Ottawa. http://www.pmprb-cepmb.gc.ca
31. Pecorino P. 2002. Should the US allow prescription drug reimports from Canada? J. Health Econ. 21(4):699-708
32. Pharm. Res. Manuf. Am. (PhRMA). 2003. Pharmaceutical Industry Profile 2003. Washington, DC: PhRMA. http://www. phrma.org
33. Product. Comm. 2001. International Pharmaceutical Price Differences. Research Report. Melbourne: Commonw. Aust.
34. Public Citizen's Congr. Watch, Mass. Public Interest Res. Group. 2000. Massachusetts Consumers Pay More for Prescription Drugs While Pharmaceutical Profits Soar: An Investigation Into Prescription Drug Price Grouping in Massachusetts. Boston: Public Citizen. http:// www.citizen.org
35. Randall B 4th, Vogt DU. 2002. Importing Prescription Drugs. Washington, DC: Congr. Res. Serv. Libr. Congr.
36. Scherer FM, Ross D. 1990. Industrial Market Structure and Economic Performance. Boston: Houghton. 3rd ed.
37. Tagliabue J. 2003. Global AIDS Fund Finding Few Answers to its Cash Shortage. New York Times, July 17
38. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, et al. 2002. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359:2188. http://www.thelancet.com
39. US Cent. Medicare Medicaid. 2003. National Health Expenditures, 2001. Table 10. Washington, DC. Accessed 28 July http://cms.hhs.gov/statistics/nhe/ historical/t10.asp
40. US Congr., Congr. Budget Off. 1996. How the Medicaid rebate on prescription drugs affects pricing in the pharmaceutical industry. Washington, DC. http:// www.cbo.gov
41. US Congr., Congr. Budget Off. 2002. Issues in designing a prescription drug benefit for Medicare. Washington, DC. http://www.cbo.gov
42. US Congr., Off. Technol. Assess. 1993. Pharmaceutical R&D: costs, risks and rewards. TA-H-522. US Gov. Print. Off. Washington, DC. http://govinfo.library. unt.edu/ota/Ota_1/DATA?1993/9336.PDF
43. US Dep. Health Hum. Serv., Off. Insp. Gen. 2002. Medicaid pharmacy: additional analyses of the actual acquisition cost of prescription drug products. Publ. A06020041, Sept. 12
44. US Gen. Account. Off. 1992. Prescription drugs: companies typically charge more in the United States than in Canada. Report to the Chairman, Subcommittee Health Environ., Comm. Energy Commer., House Represent. Sept.GAO/HRD-92-110. Washington, DC
45. US Gen. Account. Off. 1994. Prescription drugs: companies typically charge more in the United States than in the United Kingdom. Jan. GAO/HEHS-94-29. Washington, DC
46. th Congressional District of Maryland: an International Price Comparison. Unpubl. Manuscript
47. US Public Interest Group Educ. Fund. 2003. Paying the price: a 19-state survey of the high cost of prescription drugs. Accessed July 2003 http://uspirg.org/uspirg/asp?id2=10394&id3=USPIRG&/
48. Varian HR. 1996. Differential pricing and efficiency. First Monday: Peer Rev. J. Internet. pp. 1-17, http://firstfriday.org
49. Wagner JL, Congr. Budget Off. 2001. Economics of the pharmaceutical industry. Presented at Annu. Health Care Forecast Conf., 10th, Grad. Sch. Manag., Univ. Calif., Irvine
50. Woodfield A. 2001. Augmenting reference pricing of pharmaceuticals in New Zealand with strategic cross-product agreements. Pharmacoeconomics 19(4):365-77